Speaker: Emily Poh, PGY-1 Pharmacy Resident, NUH

SGLT2 inhibitor is the “New Kid on the Block” in diabetes treatment and it holds the promise of new ways to manage diabetes. This class of drugs has a novel mode of action – further glucose-lowering effect that is independent of insulin secretion. It also offers additional clinical benefits. To date, dapagliflozin, canagliflozin and empagliflozin have been approved in Singapore. In this seminar, the pharmacology and clinical evidence between the SGLT2 inhibitors will be discussed with a focus to provide guidance for appropriate use.